[Surgical treatment of acute dissecting aneurysms of the aorta].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M Ohira.
Explore the source record for details and available documents.
Comparative study of antiemetic effect on vomiting due to cancer chemotherapy was performed in 62 children with various malignant diseases. Twenty-one children were treated with metoclopramide, 23 children with domperidone and remaining 18 children received methylprednisolone. Each drug was administered intravenously after administration of anticancer agents, and repeated if necessary. The most effective antiemetics was methyl-prednisolone with effective rate of 89% in comparison with 51% of domperidone and 17% of metoclopromide treated group, respectively. Methyl-prednisolone may be useful for severe vomiting due to anticancer drugs. Safer and significantly better therapeutic efficacy was observed in the group treated with domperidone than that with metoclopromide.
A cultured cell line, P30/Ohkubo with pre-T cell phenotype, was established from an 11-year-old girl with acute lymphoblastic leukemia (ALL). According to the morphological, cytochemical and immunological analyses, P30/Ohkubo was found to have common-ALL antigen, Ia-like antigen, pan-T cell antigen, and L2 morphology with localized acid phosphatase staining, but not rosette-forming capacity with sheep erythrocytes, B1 antigen or surface immunoglobulins. Chromosome analysis revealed that P30/Ohkubo had two constant marker chromosomes [11q +, del (9)], but lacked 14q +. These findings indicate that P30/Ohkubo is a novel cultured cell line of pre-T cell phenotype. These characteristics have remained unchanged for more than 20 months since establishment of the cell line.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.